Post Doctoral Fellow - Zerra Lab in the Department of Pathology at Emory University

Atlanta, Georgia, United States -

Full Time

Start Date

Immediate

Expiry Date

20 May, 26

Salary

0.0

Posted On

19 Feb, 26

Experience

0 year(s) or above

Remote Job

Yes

Telecommute

Yes

Sponsor Visa

Skills

Immunology, Hematology, Transfusion Medicine, Pre-clinical Mouse Models, Patient Samples Analysis, Scientific Writing, Oral Communication

Industry

Higher Education

Description

Discover Your Career at Emory University Emory University is a leading research university that fosters excellence and attracts world-class talent to innovate today and prepare leaders for the future. We welcome candidates who can contribute to the excellence of our academic community. Description A postdoctoral opening is immediately available in the Zerra Lab in the Department of Pathology at Emory University School of Medicine in Atlanta. Our lab studies the initiating immune events in the response to blood-borne therapeutics, including red blood cells and factor VIII, using a combination of pre-clinical mouse models and patient samples. The underlying goal is to identify novel targets for the prevention of antibody development against these therapeutics to improve patient outcomes. The ideal candidate is a highly motivated scientist with a Ph.D. and/or M.D. with an interest in hematology and/or transfusion medicine, a strong background in immunology and the ability to work well both independently and with others on a team. MINIMUM QUALIFICATIONS: A doctoral degree or equivalent (Ph.D., M.D., ScD., D.V.M., DDS etc) in an appropriate field. Excellent scientific writing ability and strong oral communication skills. The ability to work effectively and collegially with colleagues. Additional qualifications as specified by the Principal Investigator. NOTE: Position tasks are generally required to be performed in-person at an Emory University location. Remote work from home day options may be granted at department discretion. Emory reserves the right to change remote work status with notice to employee. Additional Details Emory is an equal opportunity employer, and qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, protected veteran status or other characteristics protected by state or federal law. Emory University does not discriminate in admissions, educational programs, or employment, including recruitment, hiring, promotions, transfers, discipline, terminations, wage and salary administration, benefits, and training. Students, faculty, and staff are assured of participation in university programs and in the use of facilities without such discrimination. Emory University complies with Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veteran's Readjustment Assistance Act, and applicable executive orders, federal and state regulations regarding nondiscrimination, equal opportunity, and affirmative action (for protected veterans and individuals with disabilities). Inquiries regarding this policy should be directed to the Emory University Department of Equity and Civil Rights Compliance, 201 Dowman Drive, Administration Building, Atlanta, GA 30322. Telephone: 404-727-9867 (V) | 404-712-2049 (TDD). Emory University is committed to ensuring equal access and providing reasonable accommodations to qualified individuals with disabilities upon request. To request this document in an alternate format or to seek a reasonable accommodation, please contact the Department of Accessibility Services at accessibility@emory.edu or call 404-727-9877 (Voice) | 404-712-2049 (TDD). We kindly ask that requests be made at least seven business days in advance to allow adequate time for coordination.

Responsibilities

The role involves studying the initiating immune events in response to blood-borne therapeutics, such as red blood cells and factor VIII, utilizing pre-clinical mouse models and patient samples. The primary goal is to identify novel targets for preventing antibody development against these therapeutics to enhance patient outcomes.